VEGFA and diabetic retinopathy: A multicenter randomized study conducted by the Diabetic Retinopathy Clinical Research Network compared three usually applied intravitreal anti-VEGF inhibitors—aflibercept, ranibizumab, and bevacizumab—for DME therapy.